Filing Flows › Biocryst Pharmaceuticals (BCRX) › Recalls, complaints & regulation
Biocryst Pharmaceuticals (BCRX): clinical trials
Biocryst Pharmaceuticals (BCRX) beyond its filings: 3 active clinical trials.
Biocryst Pharmaceuticals' latest quarter
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Biocryst Pharmaceuticals have?
3 active studies on ClinicalTrials.gov, 2 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.